Prospektiver randomisierter Vergleich von mechanischen und elektronischen endoskopischen Ultraschallsystemen in Durchführungsparametern und Bildqualität: Endgültige Ergebnisse

Autor: Papanikolaou, I, Adler, A, Delicha, EM, Wegener, K, Giannakoulopoulou, E, Wiedenmann, B, Rösch, T

Publikováno v: Endoskopie heute; 20240101, Issue: Preprints

Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.

Autor: Mammen AL; Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Amato AA; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Dimachkie MM; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas USA., Chinoy H; National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK; Department of Rheumatology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK., Hussain Y; Austin Neuromuscular Center, The University of Texas Dell Medical School, Austin, Texas, USA., Lilleker JB; Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Manchester, UK; Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Salford, UK., Pinal-Fernandez I; Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Regulation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Allenbach Y; Department of Internal Medicine and Clinical Immunology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France; Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France., Boroojerdi B; UCB Pharma, Monheim, Germany., Vanderkelen M; UCB Pharma, Braine-l'Alleud, Belgium., Delicha EM; UCB Pharma, Braine-l'Alleud, Belgium., Koendgen H; UCB Pharma, Bulle, Switzerland., Farzaneh-Far R; Ra Pharmaceuticals, Cambridge, Massachusetts, USA., Duda PW; UCB Pharma, Cambridge, Massachusetts, USA., Sayegh C; UCB Pharma, Cambridge, Massachusetts, USA., Benveniste O; Department of Internal Medicine and Clinical Immunology, Sorbonne Université, Assistance Publique Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France; Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Centre de Recherche en Myologie, UMRS974, Paris, France.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2023 Feb; Vol. 5 (2), pp. e67-e76. Date of Electronic Publication: 2023 Jan 24.

Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers.

Autor: Mitsikostas DD; 1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece., Aravantinou-Fatorou K; 1st Neurology Department, Aeginition Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece., Deligianni C; Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, 2600 Copenhagen, Denmark., Kravvariti E; 1st Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, Laikon General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Korompoki E; Department of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece., Mylona M; 1st Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, Laikon General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Vryttia P; Department of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece., Papagiannopoulou G; 2nd Neurology Department, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece., Delicha EM; ASTAT, Statistics in Clinical Research, 16675 Glyfada, Greece., Dellis A; 2nd Surgery Department, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece., Tsivgoulis G; 2nd Neurology Department, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece., Dimopoulos MA; Department of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece., Amanzio M; Department of Psychology, University of Turin, Via Verdi 10, 10124 Turin, Italy., Sfikakis PP; 1st Department of Propaedeutic Internal Medicine, Joint Rheumatology Program, Laikon General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Publikováno v: Vaccines [Vaccines (Basel)] 2021 Oct 14; Vol. 9 (10). Date of Electronic Publication: 2021 Oct 14.

5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.

Autor: Marzo-Ortega H; National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals National Health Service Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. Electronic address: h.marzo-ortega@leeds.ac.uk., Sieper J; University Clinic Benjamin Franklin, Berlin, Germany., Kivitz AJ; Altoona Center for Clinical Research, Duncansville, PA, USA., Blanco R; Hospital Universitario Marqués de Valdecilla, Santander, Spain., Cohen M; McGill University, Montreal, QC, Canada., Pavelka K; Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic., Delicha EM; Novartis Pharma, Basel, Switzerland., Stefanska A; Novartis Ireland, Dublin, Ireland., Richards HB; Novartis Pharma, Basel, Switzerland., Rohrer S; Novartis Pharma, Basel, Switzerland.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2020 Jun; Vol. 2 (6), pp. e339-e346.

Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.

Autor: McInnes IB; Institute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK. Electronic address: Iain.McInnes@glasgow.ac.uk., Mease PJ; Swedish Medical Centre-Providence St Joseph Health and University of Washington, Seattle, WA, USA., Kivitz AJ; Altoona Centre for Clinical Research, Duncansville, PA, USA., Nash P; School of Medicine, Griffith University, QLD, Australia., Rahman P; Memorial University, St John's, NL, Canada., Rech J; Friedrich-Alexander-University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany., Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK., Kirkham B; Guy's & St Thomas' NHS Foundation Trust, London, UK., Navarra S; University of Santo Tomas Hospital, Manila, Philippines., Belsare AD; Novartis Healthcare, Hyderabad, India., Delicha EM; Novartis Pharma AG, Basel, Switzerland., Pricop L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2020 Apr; Vol. 2 (4), pp. e227-e235.